There is no single 'peptide law'

The United Kingdom has no statute that names peptides as a class and declares them lawful or unlawful. Whether a given compound may be supplied, and on what terms, is decided product by product. The question is not 'is this a peptide?' but 'is this a medicinal product, and if so, is it licensed?'

That distinction matters to researchers because the same molecule can sit on either side of the line depending on presentation and intended use. A lyophilised powder supplied as a laboratory reagent and a vial presented as a treatment for a named condition are treated differently under the same law.

What makes something a medicinal product

The controlling definitions sit in the Medicines Act 1968 and are carried into the Human Medicines Regulations 2012 (SI 2012/1916). UK law uses two connected tests, usually described as 'presentation' and 'function'.

  • Presentation: a product is a medicinal product if it is presented as having properties for treating or preventing disease in human beings.
  • Function: a product is also a medicinal product if it may be used in, or administered to, human beings either to restore, correct or modify physiological functions by exerting a pharmacological, immunological or metabolic action, or to make a medical diagnosis.

Peptides are, by their nature, pharmacologically active. A compound that exerts a metabolic or physiological effect in humans can therefore fall within the function limb even where no therapeutic claim is made for it. The label on the vial does not settle the question on its own; a regulator may look at the whole picture, including labelling, website copy, calculators, customer reviews and the manner in which the product is expected to be used.

The MHRA is the licensing authority

The Medicines and Healthcare products Regulatory Agency (MHRA) is the UK licensing authority for medicines — an executive agency sponsored by the Department of Health and Social Care. A medicinal product placed on the UK market requires a marketing authorisation, and supplying one without an authorisation is an offence.

Some peptides in clinical use hold a UK marketing authorisation — semaglutide and tirzepatide among the incretin mimetics — and their status is not in doubt. Many of the compounds catalogued on this site hold no UK marketing authorisation and are supplied as research reagents rather than as medicines.

The other bodies at the boundary

The MHRA is not the only regulator with an interest. Depending on the product and the activity, several others may be engaged:

  • The Advertising Standards Authority (ASA) applies the advertising codes, including the prohibition on advertising prescription-only medicines to the public.
  • The General Pharmaceutical Council (GPhC) regulates pharmacies and registered pharmacy premises.
  • Trading Standards and the Competition and Markets Authority address consumer-protection and unfair-trading questions.
  • The Veterinary Medicines Directorate (VMD) has jurisdiction where a product is presented for animals.
  • HM Revenue & Customs and customs authorities enforce import and movement controls.

In 2026 the MHRA, the ASA and the GPhC issued a joint warning against promoting unlicensed and pipeline weight-management medicines. The warning is a reminder that enforcement can be shared rather than exercised by a single body.

'Research use only' is not a safe harbour

The phrase 'research use only' records a stated purpose. It is not a statutory exemption, and it does not, by itself, take a product outside the Human Medicines Regulations 2012. Regulators assess what a product is, how it is described and how it is supplied — not only the wording on the label. A supplier that presents a compound as suitable for human use, or invites use through calculators, testimonials or advertising, cannot rely on the label to change the classification.

For that reason this site frames every compound as a research compound, describes the published research rather than a therapeutic outcome, and gives no dosing or consumption guidance.

The legitimate research route

Research that does involve administering a compound to human participants in the UK is conducted as a clinical trial of an investigational medicinal product (CTIMP). Since 28 April 2026 the amended clinical-trials regulations have been in force, following a 12-month implementation period. The reforms align MHRA and Research Ethics Committee review into a combined process and constitute the largest package of clinical-trial reform in more than 20 years. Non-CTIMP research has been aligned to the same framework.

That route — prospective approval, ethics review and good clinical practice — is the one that generates the human evidence this reference grades. Where a compound has no such evidence, the grade reflects it.

Why the boundary matters

For the reader, the practical point is narrow. A peptide's legal position in the UK is a matter of classification and licensing, not of the word 'peptide'. The evidence grade on a compound profile describes the research record; the UK status describes the regulatory footing. They are separate questions, and collapsing them is where most of the confusion — and most of the enforcement risk — begins.

This article is AI-researched and editorially reviewed. It is provided for research and educational purposes only and is not medical advice. Research peptides are not licensed for human consumption in the UK.